[Federal Register Volume 81, Number 172 (Tuesday, September 6, 2016)]
[Notices]
[Pages 61218-61219]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-21273]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-16-16XD]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) has submitted
the following information collection request to the Office of
Management and Budget (OMB) for review and approval in accordance with
the Paperwork Reduction Act of 1995. The notice for the proposed
information collection is published to obtain comments from the public
and affected agencies.
Written comments and suggestions from the public and affected
agencies concerning the proposed collection of information are
encouraged. Your comments should address any of the following: (a)
Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the agency, including
whether the information will have practical utility; (b) Evaluate the
accuracy of the agencies estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (c) Enhance the quality, utility, and clarity of
the information to be collected; (d) Minimize the burden of the
collection of information on those who are to respond, including
through the use of appropriate automated, electronic, mechanical, or
other technological collection techniques or other forms of information
technology, e.g., permitting electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to [email protected]. Written comments and/or
suggestions regarding the items contained in this notice should be
directed to the Attention: CDC Desk Officer, Office of Management and
Budget, Washington, DC 20503 or by fax to (202) 395-5806. Written
comments should be received within 30 days of this notice.
Proposed Project
Practice Patterns Related to Opioid Use during Pregnancy and
Lactation--New--National Center for Chronic Disease Prevention and
Health Promotion (NCCDPHP), Centers for Disease Control and Prevention
(CDC).
Background and Brief Description
Over the past decade, the prevalence of maternal opioid use during
pregnancy has steadily increased. The use of opioids or other
psychoactive substances, either by illicit abuse or by nonmedical abuse
of prescription opioids, increases the risks for health and social
problems for both mother and infant. For example, maternal substance
abuse during pregnancy increases the risk of preterm birth, low birth
weight, perinatal death, and neonatal abstinence syndrome (NAS). For
many women, and some at-risk women in particular, prenatal visits may
be the only time they routinely see a physician. Because obstetrician-
gynecologists (OB/GYNs) are the principal health care providers for
women, OB/GYNs are well situated to screen for substance use and to
treat or encourage cessation of substance use during pregnancy. Thus,
it is important
[[Page 61219]]
to understand current provider knowledge, attitudes, and practices
regarding maternal opioid use.
CDC, in collaboration with the American College of Obstetricians
and Gynecologists (ACOG), plans to conduct a survey to address this gap
in knowledge. Survey respondents will be ACOG Fellows and Junior
Fellows who have a current medical license and are in medical practice
focused on women's health. ACOG is separated into 11 districts, one of
which represents OB/GYN members who are in the U.S. military. The
remaining 10 ACOG districts correspond to geographic regions that
encompass the entire United States and Canada. Survey invitations will
be sent to a quasi-random sample of ACOG members in each district.
CDC and ACOG estimate that 1,500 individuals will be contacted in
order to obtain a study target of 600 respondents. The initial
invitation will be distributed by email with instructions on completing
a web-based version of the questionnaire. Three to four months after
the initial invitation, a paper version of the questionnaire will be
distributed to individuals who have not completed the online version.
The estimated number of respondents for the full web-based or paper
questionnaire is 420 and the estimated burden per response is 15
minutes. Approximately 6 weeks after the second recruitment attempt,
ACOG will distribute a short version of the questionnaire to any non-
responders. The estimated number of responses for the short version of
the questionnaire is 180 and the estimated burden per response is 5
minutes. An overall 40% response rate is expected.
The survey will collect information about provider attitudes and
beliefs regarding maternal opioid use, their screening and referral
practices for pregnant or postpartum patients, barriers to screening
and treating pregnant and postpartum patients for opioid use, and
resources that are needed to improve treatment and referral. No
information will be collected about individual patients. Survey
administration and data management will be conducted by ACOG, and
participation is voluntary. De-identified response data will be shared
with CDC for analysis. Findings will be used to create recommendations
for educational programs and patient care. The total estimated
annualized burden hours are 120. There are no costs to participants
other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondents Form name respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
OB/GYNs caring for pregnant women.. Practice Patterns related 420 1 15/60
to Opioid Use during
Pregnancy and Lactation--
Full survey.
Practice Patterns related 180 1 5/60
to Opioid Use during
Pregnancy and Lactation--
Short introduction and
survey.
----------------------------------------------------------------------------------------------------------------
Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2016-21273 Filed 9-2-16; 8:45 am]
BILLING CODE 4163-18-P